Dr Vincent Charlon
Vincent Charlon has 30 years of global clinical development and management experience in biotech, pharma and CRO companies. During the past ten years as CEO of Anergis SA in Lausanne, Vincent Charlon raised over 55 million CHF and managed the discovery, preclinical and clinical development of Anergis proprietary allergen immunotherapy products. Anergis conducted one Phase IIA and four Phase IIB studies with its lead-product candidate designed to treat birch pollen allergy.
After his Pharmacology PhD thesis from Grenoble, France in 1988, Vincent Charlon worked for two years as scientist in a Phase 1 unit (today Optimed Eurofins). In 1990, he joined Hoffmann La Roche headquarters in Basel as Clinical Research Scientist and then Hoffmann La Roche Inc. Nutley, USA, as Director of Clinical Research. Vincent Charlon held clinical development responsibilities for several international projects and was the first author of an approved global new drug application for a cardiovascular product.
He was involved in numerous meetings with the US FDA and European regulatory authorities. From 1998 to 2006, Vincent Charlon was CEO of Hesperion Ltd., the contract research organization (CRO) in charge of the design and conduct of all initial clinical trials for Actelion [now a Johnson & Johnson company]. Hesperion developed as a profitable CRO, grew from 3 to 200 employees located in eight countries, serving over a hundred international clients. During that time, Hesperion completed two company acquisitions and integrations into Hesperion. Hesperion was acquired by Cerep SA in 2004.
Cutting-Edge Cancer Immunotherapy
60F avenue Rockefeller
69008 Lyon, FRANCE